Skip to main content

Episode #4: Scaling Biotech companies in challenging times

Life Sciences Connect

The Biotech sector is a key player in driving biopharma innovation and developing ground-breaking treatments for patients. Supporting the growth of this sector is vital to ensure that R&D efforts continue, both now and in the future. However, like most industries, this sector faces a complex set of challenges.

Over the past six months, the biotech sector has rapidly pivoted to respond to the challenge of the COVID-19 pandemic. Companies have grappled with this new reality by adapting to a new way of working and by forging new partnerships across the sector. In the next six months, companies will need to navigate the challenges associated with Brexit including planning for possible workforce related issues and a possible new regulatory environment.

In the fourth episode of Life Sciences Connect, we explore the challenges and opportunities facing the Biotech Industry.

This episode is led by our host Karen Taylor. Karen is joined by Hanno Ronte, Partner at Monitor Deloitte, Frances Cousins, Partner in Deloitte’s Healthcare Technology practice and Steve Bates, CEO of the UK BioIndustry Association.

This episode explores:

  • The challenges and opportunities Biotech companies have faced as they pivoted to respond to COVID-19
  • The legacy that the COVID-19 pandemic will leave for the Biotech Industry
  • The possible impact of Brexit on the Biotech industry

Find out more

If you are interested in any of the topics discussed during this episode, please find useful links below:

Stay up to date with Deloitte Centre for Health Solutions

Life Sciences ConnectVisit the Life Sciences Connect podcast library for the full collection of episodes.

Did you find this useful?

Thanks for your feedback

If you would like to help improve further, please complete a 3-minute survey